Risk of ovarian cancer and the NF-kB pathway: Genetic association with IL1A and TNFSF10

Cancer Research

Volumn 74, Issue 3, 2014, Pages 852-861

  Charbonneau, Bridget ^a   Block, Matthew S ^a   Bamlet, William R ^a   Vierkant, Robert A ^a   Kalli, Kimberly R ^a   Fogarty, Zachary ^a   Rider, David N ^a   Sellers, Thomas A ^b   Tworoger, Shelley S ^c,d   Poole, Elizabeth ^c,d   Risch, Harvey A ^e   Salvesen, Helga B ^f,g   Kiemeney, Lambertus A ^i,j   Baglietto, Laura ^k,l   Giles, Graham G ^k,l,n   Severi, Gianluca ^k,l   Trabert, Britton ^q   Wentzensen, Nicolas ^q   Chenevix Trench, Georgia ^o,p   Whittemore, Alice S ^r   Sieh, Weiva ^r   Chang Claude, Jenny ^w   Bandera, Elisa V ^af   Orlow, Irene ^g   Terry, Kathryn ^c,d   Goodman, Marc T ^s   Thompson, Pamela J ^s   Cook, Linda S ^ai   Rossing, Mary Anne ^aj,ak   Ness, Roberta B ^al   Narod, Steven A ^ao   Kupryjanczyk, Jolanta ^g   Lu, Karen ^g   Butzow, Ralf ^aw   Dork, Thilo ^x   Pejovic, Tanja ^ax,ay   Campbell, Ian ^m,o   Le, Nhu D ^ap   Bunker, Clareann H ^az   Bogdanova, Natalia ^x   Runnebaum, Ingo B ^y   Eccles, Diana ^bb   Paul, James ^bc   Wu, Anna H ^t   Gayther, Simon A ^t   Hogdall, Estrid ^bk,bl   Heitz, Florian ^z,ab   Kaye, Stanley B ^bd   Karlan, Beth Y ^s   Anton Culver, Hoda ^v   Gronwald, Jacek ^au   Hogdall, Claus K ^bm   Lambrechts, Diether ^bn,bo   Fasching, Peter A ^u,ac   Menon, Usha ^be,bf,bg   Schildkraut, Joellen ^g,br   Pearce, Celeste Leigh ^t   Levine, Douglas A ^ag   Kjaer, Susanne Kruger ^bk,bm   Cramer, Daniel ^c,d   Flanagan, James M ^bh   Phelan, Catherine M ^b   Brown, Robert ^bh   Massuger, Leon F A G ⁱ   Song, Honglin ^bj   Doherty, Jennifer A ^bs   Krakstad, Camilla ^f,g   Liang, Dong ^an   Odunsi, Kunle ^ah   Berchuck, Andrew ^bq   Jensen, Allan ^bk   Lubinski, Jan ^au   Nevanlinna, Heli ^aw   Bean, Yukie T ^ax,ay   Lurie, Galina ^bt   Ziogas, Argyrios ^v   Walsh, Christine ^s   Despierre, Evelyn ^bp   Brinton, Louise ^q   Hein, Alexander ^ac   Rudolph, Anja ^w   Dansonka Mieszkowska, Agnieszka ^g   Olson, Sara H ^g   Harter, Philipp ^z,ab   Tyrer, Jonathan ^bj   Vitonis, Allison F ^c   Brooks Wilson, Angela ^ap,aq   Aben, Katja K ^i,j   Pike, Malcolm C ^t,ah   Ramus, Susan J ^t   Wik, Elisabeth ^f,h   Cybulski, Cezary ^au   Lin, Jie ^am   Sucheston, Lara ^ah   Edwards, Robert ^az,ba   McGuire, Valerie ^r   Lester, Jenny ^s   Du Bois, Andreas ^z,ab   Lundvall, Lene ^bm   Wang Gohrke, Shan ^ae   Szafron, Lukasz M ^g   Lambrechts, Sandrina ^bp   Yang, Hannah ^q   Beckmann, Matthias W ^ac   Pelttari, Liisa M ^aw   Van Altena, Anne M ⁱ   Van Den Berg, David ^t   Halle, Mari K ^f,g   Gentry Maharaj, Aleksandra ^be,bf,bg   Schwaab, Ira ^aa   Chandran, Urmila ^af   Menkiszak, Janusz ^av   Ekici, Arif B ^ad   Wilkens, Lynne R ^bt   Leminen, Arto ^aw   Modugno, Francesmary ^az,ba   Friel, Grace ^ah   Rothstein, Joseph H ^r   Vergote, Ignace ^bp   Garcia Closas, Montserrat ^bd,bi   Hildebrandt, Michelle A T ^am   Sobiczewski, Piotr ^at   Kelemen, Linda E ^ar,as   Pharoah, Paul D P ^bj   Moysich, Kirsten ^ah   Knutson, Keith L ^a   Cunningham, Julie M ^a   Fridley, Brooke L ^bu   Goode, Ellen L ^a   more..

^a MAYO CLINIC   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e YALE UNIVERSITY   (United States)

^f UNIVERSITY OF BERGEN   (Norway)

^g Department of Gynecology and Obstetrics ^*  (United States)

^h HAUKELAND UNIVERSITY HOSPITAL   (Norway)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j Netherlands Comprehensive Cancer Organisation The Netherlands   (Netherlands)

^k CANCER EPIDEMIOLOGY CENTRE   (Australia)

^l Genetic and Analytical Epidemiology   (Netherlands)

^m UNIVERSITY OF MELBOURNE   (Australia)

ⁿ MONASH UNIVERSITY   (Australia)

^o PETER MACCALLUM CANCER CENTRE   (Australia)

^p QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^q NATIONAL CANCER INSTITUTE   (United States)

^r STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s CEDARS SINAI MEDICAL CENTER   (United States)

^t UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^u UNIVERSITY OF CALIFORNIA   (United States)

^v UNIVERSITY OF CALIFORNIA   (United States)

^w GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^x HANNOVER MEDICAL SCHOOL   (Germany)

^y JENA UNIVERSITY HOSPITAL   (Germany)

^z DR HORST SCHMIDT KLINIKEN   (Germany)

^aa Institut Für Humangenetik Wiesbaden   (Germany)

^ab KLINIKEN ESSEN MITTE   (Germany)

^ac UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^ad UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^ae UNIVERSITY OF ULM   (Germany)

^af ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^ag MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^ah ROSWELL PARK CANCER INSTITUTE   (United States)

^ai UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^aj Fred Hutchinson Cancer Research Center   (United States)

^ak UNIVERSITY OF WASHINGTON   (United States)

^al UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^am UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^an TEXAS SOUTHERN UNIVERSITY   (United States)

^ao UNIVERSITY OF TORONTO   (Canada)

^ap BRITISH COLUMBIA CANCER AGENCY   (Canada)

^aq SIMON FRASER UNIVERSITY   (Canada)

^ar ALBERTA HEALTH SERVICES   (Canada)

^as UNIVERSITY OF CALGARY   (Canada)

^at INSTITUTE OF ONCOLOGY   (Poland)

^au Department of Genetics and Pathology International Hereditary Cancer Center   (United States)

^av POMERANIAN MEDICAL UNIVERSITY   (Poland)

^aw HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^ax OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^ay OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^az UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^ba UNIVERSITY OF PITTSBURGH   (United States)

^bb UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^bc BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^bd INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^be Gynaecological Cancer Research Centre   (United Kingdom)

^bf Institute for Women's Health   (United Kingdom)

^bg UNIVERSITY COLLEGE LONDON   (United Kingdom)

^bh IMPERIAL COLLEGE LONDON   (United Kingdom)

^bi Breakthrough Breast Cancer Research Centre   (United Kingdom)

^bj UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^bk DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^bl UNIVERSITY OF COPENHAGEN   (Denmark)

^bm International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^bn DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^bo UNIVERSITY OF LEUVEN   (Belgium)

^bp UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^bq DUKE UNIVERSITY MEDICAL CENTER   (United States)

^br DUKE CANCER INSTITUTE   (United States)

^bs DARTMOUTH MEDICAL SCHOOL   (United States)

^bt UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^bu UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INTERLEUKIN-1ALPHA; NF-KAPPA B; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84893837618     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1051     Document Type: Article

References (60)

1. Fleming JS, Beaugie CR, Haviv I, Chenevix-Trench G, Tan OL. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 2006;247: 4-21.
2. Negri E, Franceschi S, Tzonou A, Booth M, La Vecchia C, Parazzini F, et al. Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 1991;49:50-6.
3. Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2011;105:1436-42.
4. Ness RB, Grisso JA, Klapper J, Schlesselman JJ, Silberzweig S, Vergona R, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid hormones and reproductions. Am J Epidemiol 2000;152:233-41.
5. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002;94:32-8.
6. Franco EL, Duarte-Franco E. Ovarian cancer and oral contraceptives. Lancet 2008;371:277-8.
7. King SM, Hilliard TS, Wu LY, Jaffe RC, Fazleabas AT, Burdette JE. The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer. Endocr Relat Cancer 2011;18:627-42.
8. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1995; 4:447-51.
9. Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin WZ, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a populationbased study. Lancet Oncol 2011;12:900-4.
10. Augoulea A, Alexandrou A, Creatsa M, Vrachnis N, Lambrinoudaki I. Pathogenesis of endometriosis: the role of genetics, inflammation and oxidative stress. Arch Gynecol Obstet 2012;286:99-103.
11. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012;13:385-94.
12. Merritt MA, Green AC, Nagle CM, Webb PM. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008;122:170-6.
13. Wehner AP. Biological effects of cosmetic talc. Food Chem Toxicol 1994;32:1173-84.
14. Baandrup L, Faber MT, Christensen J, Jensen A, Andersen KK, Friis S, et al. Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand 2013;92:245-55.
15. Trabert B, Ness R, Lo-Ciganic W, Murphy M, Goode E, Poole E, et al. A pooled analysis of analgesic drug use and risk of invasive epithelial ovarian cancer. J Natl Cancer Inst. In press.
16. White KL, Schildkraut JM, Palmieri RT, Iversen ES Jr, Berchuck A, Vierkant RA, et al. Ovarian cancer risk associated with inherited inflammation-related variants. Cancer Res 2012;72:1064-9.
17. Hogquist KA, Nett MA, Unanue ER, Chaplin DD. Interleukin 1 is processed and released during apoptosis. Proc Natl Acad Sci U S A 1991;88:8485-9.
18. Papacleovoulou G, Critchley HO, Hillier SG, Mason JI. IL1alpha and IL4 signalling in human ovarian surface epithelial cells. J Endocrinol 2011;211:273-83.
19. Mori N, Prager D. Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Blood 1996;87:3410-7.
20. Bhat-Nakshatri P, Newton TR, Goulet R Jr, Nakshatri H. NF-kappaB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1alpha. Proc Natl Acad Sci U S A 1998;95:6971-6.
21. White KL, Rider DN, Kalli KR, Knutson KL, Jarvik GP, Goode EL. Genomics of the NF-kappaB signaling pathway: hypothesized role in ovarian cancer. Cancer Causes Control 2011;22:785-801.
22. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
23. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25:280-8.
24. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-6.
25. Hsu S, KimM, Hernandez L, Grajales V, Noonan A, Anver M, et al. IKK-e coordinates invasion and metastasis of ovarian cancer. Cancer Res 2012;72:5494-504.
26. Van Antwerp DJ, Martin SJ, Verma IM, Green DR. Inhibition of TNFinduced apoptosis by NF-kappa B. Trends Cell Biol 1998;8:107-11.
27. Gonzalez-Ramos R, Defrere S, Devoto L. Nuclear factor-kappaB: a main regulator of inflammation and cell survival in endometriosis pathophysiology. Fertil Steril 2012;98:520-8.
28. Pharoah PDP, Tsai Y-Y, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013;45:362-70.
29. International HapMap Project. Available from: http://www.hapmap. org; accessed November 2008.
30. 1000 Genomes Project. A deep catalog of human genetic variation. Available from: http://www.1000genomes.org/; accessed April 2010.
31. SeattleSNPs. Available from: http://pga.gs.washington.edu/; accessed November 2008.
32. IIPGA. Innate immunity in heart, lung and blood disease. Programs for genomic applications. Available from: http://web.archive.org/web/ 20090714233138/http://innateimmunity.net/; accessed November 2008.
33. National Institute of Environmental Health Sciences. Environmental Genome Project. NIEHS SNPs program. Available from: http://egp.gs. washington.edu; accessed November 2008.
34. TargetScan Human. Prediction of microRNA targets. Available from: http://www.targetscan.org/; accessed September 2009.
35. microRNA.org. Predicted microRNA targets & target downregulation scores. Experimentally observed expression patterns. Available from: http://www.microrna.org/microrna/home.do; accessed September 2009.
36. Sicotte H, Rider D, Poland G, Dhiman N, Kocher J-P. SNPPicker: high quality tag SNP selection across multiple populations. BMC Bioinformatics 2011;12:129.
37. Kermani BG, inventor; Illumina, Inc., assignee. Artificial intelligence and global normalization methods for genotyping. United States patent US 7467117 B2. 2008.
38. Teo YY, Inouye M, Small KS, Gwilliam R, Deloukas P, Kwiatkowski DP, et al. A genotype calling algorithm for the Illumina BeadArray platform. Bioinformatics 2007;23:2741-6.
39. Giannoulatou E, Yau C, Colella S, Ragoussis J, Holmes CC. GenoSNP: a variational Bayes within-sample SNP genotyping algorithm that does not require a reference population. Bioinformatics 2008; 24:2209-14.
40. Sankararaman S, Sridhar S, Kimmel G, Halperin E. Estimating local ancestry in admixed populations. Am J Hum Genet 2008;82: 290-303.
41. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genomewide association studies. Nat Genet 2006;38:904-9.
42. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and populationbased linkage analyses. Am J Hum Genet 2007;81:559-75.
43. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010;26:2336-7.
44. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004;74:765-9.
45. Hata Y, Nakaoka H, Yoshihara K, Adachi S, Haino K, Yamaguchi M, et al. A nonsynonymous variant of IL1A is associated with endometriosis in Japanese population. J Hum Genet 2013;58:517-20.
46. Kawaguchi Y, Tochimoto A, Hara M, Kawamoto M, Sugiura T, Saito S, et al. Contribution of single nucleotide polymorphisms of the IL1A gene to the cleavage of precursor IL-1alpha and its transcription activity. Immunogenetics 2007;59:441-8.
47. Zheng Y, Humphry M, Maguire JJ, Bennett MR, Clarke MC. Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1alpha, controlling necrosis-induced sterile inflammation. Immunity 2013;38:285-95.
48. Apte RN, Voronov E. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol Rev 2008;222:222-41.
49. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004;4:29-42.
50. Hoeft B, Becker N, Deeg E, Beckmann L, Nieters A. Joint effect between regular use of non-steroidal anti-inflammatory drugs, variants in inflammatory genes and risk of lymphoma. Cancer Causes Control 2008;19:163-73.
51. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75.
52. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004;4:333-9.
53. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8: 782-98.
54. Steinwede K, Henken S, Bohling J, Maus R, Ueberberg B, Brumshagen C, et al. TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. J Exp Med 2012;209:1937-52.
55. McGrath EE, MarriottHM, Lawrie A, Francis SE, Sabroe I, Renshaw SA, et al. TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation. J Leukoc Biol 2011;90:855-65.
56. Pomerantz JL, Denny EM, Baltimore D. CARD11 mediates factorspecific activation of NF-kappaB by the T cell receptor complex. EMBO J 2002;21:5184-94.
57. Shinohara H, Yasuda T, Aiba Y, Sanjo H, Hamadate M, Watarai H, et al. PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1. J Exp Med 2005;202: 1423-31.
58. Hara H, Wada T, Bakal C, Kozieradzki I, Suzuki S, Suzuki N, et al. The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity 2003;18:763-75.
59. Hara H, Ishihara C, Takeuchi A, Xue L, Morris SW, Penninger JM, et al. Cell type-specific regulation of ITAM-mediated NF-kappaB activation by the adaptors, CARMA1 and CARD9. J Immunol 2008;181:918-30.
60. Blonska M, Lin X. NF-kappaB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res 2011;21:55-70.